

Human MSLN Sandwich ELISA Kit Datasheet

Please read it entirely before use

Catalogue Number: KE00383

Size: 96T

Sensitivity: 3.7 pg/mL Range: 39.1-2500 pg/mL

Usage: For the quantitative detection of human MSLN concentrations in serum, plasma, cell culture supernatant, urine and

saliva.


This product is for research use only and not for use in human or animal therapeutic or diagnostic.

Table of content	page
1. Background	3
2. Principle	3
3. Required Materials	3
4. Kit Components and Storage	
5. Safety Notes	4
6. Sample Collection and Storage	4
7. Regent Preparation	5
8. Assay Procedure Summary	6
9. Validation Data	7
9.1 Standard curve	7
9.2 Precision	7
9.3 Recovery	8
9.4 Sample values	8
9.5 Sensitivity	8
9.6 Linearity	9
9.7 Specificity	9
10 Poforoncos	

1. Background

Mesothelin (MSLN) is a glycosylphosphatidylinositol-linked membrane glycoprotein which is highly expressed in a variety of tumors and is also expressed in mesothelial cells of healthy individuals, but at low levels. Therefore, it can be considered as a promising target protein for tumor-targeted therapy. In the tumor environment, MSLN plays an important role in survival, proliferation, and migration/invasion of cancer cells as well as in drug resistance. Over the years, evidence has accumulated with regards to the importance of MSLN as a tumor-associated antigen (TAA) overexpressed in almost one-third of human cancers. (PMID: 35795680)

2. Principle



Sandwich ELISA structure (Detection antibody labeled with HRP)

A capture antibody is pre-coated onto the bottom of wells which binds to analyte of interest. A detection antibody labeled with HRP also binds to the analyte. TMB acts as the HRP substrate and the solution color will change from colorless to blue. A stop solution containing sulfuric acid turns solution yellow. The color intensity is proportional to the quantity of bound protein which is measurable at 450 nm with the correction wavelength set at 630 nm.

3. Required Materials

- 3.1 A microplate reader capable of measuring absorbance at 450 nm with the correction wavelength set at 630 nm.
- 3.2 Calibrated, adjustable precision pipettes and disposable plastic tips. A manifold multi-channel pipette is recommended for large assays.
- 3.3 Plate washer: automated or manual.
- 3.4 Absorbent paper towels.
- 3.5 Glass or plastic tubes to prepare standard and sample dilutions.
- 3.6 Beakers and graduated cylinders.
- 3.7 Log-log or semi-log graph paper or computer and software for ELISA data analysis. A four-parameter logistic (4-PL) curve-fit is recommended.

4. Kit Components and Storage

Microplate - antibody coated 96-well microplate (8 well × 12 strips)	1 plate	Unopened Kit:	
Protein standard - 5000 pg/bottle; lyophilized	2 bottles	·	
Detection antibody, HRP-conjugated (100×) - 120 µL/vial*	1 vial	Store at 2-8°C for 6 months or -	
Sample Diluent PT 4B1 - 30 mL/bottle	1 bottle	20°C for 12 months.	
Detection Diluent - 30 mL/bottle	1 bottle	Opened Kit:	
Wash Buffer Concentrate (20×) - 30 mL/bottle	1 bottle	All reagents stored at 2-8°C for	
Tetramethylbenzidine Substrate (TMB) - 12 mL/bottle	1 bottle	<u> </u>	
Stop Solution - 12 mL/bottle	1 bottle	7 days.	
		Please use a new standard	
Plate Cover Seals	4 pieces	for each assay.	

^{*} Centrifugation immediately before use

5. Safety Notes

- 5.1 Avoid any skin and eye contact with Stop Solution and TMB. In case of contact, wash thoroughly with water.
- 5.2 Do not use the kit after the expiration date.
- 5.3 Do not mix or substitute reagents or materials from other kit lots or other sources.
- 5.4 Be sure to wear protective equipment such as gloves, masks and goggles during the experiment.
- 5.5 When using an automated plate washer, adding a 30 second soak period following the addition of Wash Buffer to improve assay precision

6. Sample Collection and Storage

- 6.1 Serum: Allow blood samples to clot for 30 minutes, followed by centrifugation for 15 minutes at 1000xg. Clear serum can be assayed immediately or aliquoted and stored at -20°C. Avoid repeated freeze-thaw cycles.
- 6.2 Plasma: Use EDTA, heparin, or citrate as an anticoagulant for plasma collection. Centrifuge for 15 minutes at 1000xg within 30 minutes of collection. The plasma can be assayed immediately or aliquoted and stored at -20°C. Avoid repeated freeze-thaw cycles.
- 6.3 Cell Culture Supernatant: Remove particulates by centrifugation for 5 minutes at 500xg and assay immediately or aliquot and store samples at \leq -20°C. Avoid repeated freeze-thaw cycles.
- 6.4 Urine: Collect urine samples and centrifuge for 20 minutes at 1000xg. Collect the aqueous layer, assay immediately or aliquot and store samples at \leq -20°C. Avoid repeated freeze-thaw cycles.
- 6.5 Saliva: Collect saliva samples and centrifuge for 5 minutes at 10,000 \times g. Collect the aqueous layer, assay immediately or aliquot and store samples at \leq -20°C. Avoid repeated freeze-thaw cycles.


7. Regent Preparation

- **7.1 Wash Buffer (1X):** If crystals have formed in the concentrate, warm to room temperature and mix gently until the crystals have completely dissolved. Add 30 mL of Wash Buffer Concentrate(20X) to 570 mL deionized or distilled water to prepare 1X Wash Buffer.
- **7.2 Detection Antibody, HRP-conjugated(1X):** Dilute 100X Detection Antibody, HRP-conjugated 1:100 using Detection Diluent prior to assay. Suggested 1:100 dilution: $10 \,\mu$ L 100X Detection Antibody, HRP-conjugated + 990 μ L Detection Diluent (Centrifuge the 100X Detection Antibody solution, HRP-conjugated for a few seconds prior to use).
- **7.3 Sample Dilution:** Different samples should be diluted with corresponding Sample Diluent, samples may require further dilution if the readout values are higher than the highest standard OD reading. Variations in sample collection, processing and storage may affect the results of the measurement.

Recommended Dilution for different sample types: 1:40 or 1:80 is recommended for human serum and plasma; 1:2 or 1:4 is recommended for cell culture supernatant; 1:4 or 1:8 is recommended for urine; 1:2 or 1:4 is recommended for saliva.

7.4 Standard Serial Dilution:

Add 2 mL Sample Diluent PT 4B1 in protein standard.



8. Assay Procedure Summary

Bring all reagents to room temperature before use (Detection antibody, HRP-conjugated can be used immediately). To avoid cross-contamination, change pipette tips between additions of each standard level, between sample additions, and between reagent additions. Also, use separate reservoirs for each reagent.


- 8.1 Take out the required number of microplate strips and return excess strips to the foil pouch containing the drying reagent pack and reseal; store at 4°C immediately. Microplate strips should be used in one week.
- 8.2 Preset the layout of the microplate, including control group, standard group and sample group, add 100 µL of each standard and sample to the appropriate wells. (Make sure sample addition is uninterrupted and completed within 5 to 10 minutes, It is recommended to assay all standards, controls, and samples in duplicate).
- 8.3 Seal plate with cover seal, pressing it firmly onto top of microwells. Incubate the plate for 2 hours at 37°C. 8.4 Wash
- 1) Gently remove the cover seal. Discard the liquid from wells by aspirating or decanting. Remove any residual solution by tapping the plate a few times on fresh paper towels.
- 2) Wash 4 times with 1X Wash Buffer, using at least 350-400 μ L per well. Following the last wash, firmly tap plates on fresh towels 10 times to remove residual Wash Buffer. Avoid getting any towel fibers in the wells or wells drying out completely. 8.5 Add 100 μ L of 1X Detection antibody, HRP-conjugated solution (refer to Reagent Preparation7.2) to each well. Seal plate with cover seal and incubate for 40 minutes at 37°C.
- 8.6 Repeat wash step in 8.4.
- 8.7 Signal development: Add 100 μ L of TMB substrate solution to each well, protected from light. Incubate for 15 to 20 minutes. Substrate Solution should remain colorless until added to the plate.
- 8.8 Quenching color development: Add 100 μ L of Stop Solution to each well in the same order as addition of the TMB substrate. Mix by tapping the side of the plate gently. NB: Avoid skin and eye contact with the Stop solution.
- 8.9 Read results: Immediately after adding Stop solution read the absorbance on a microplate reader at a wavelength of 450 nm. If possible, perform a double wavelength readout (450 nm and 630 nm).
- 8.10 Data analysis: Calculate the average of the duplicate readings (OD value) for each standard and sample, and subtract the average of the zero standard absorbance. Construct a standard curve by plotting the mean absorbance for each standard on the y-axis against the concentration on the x-axis, use four-parameter logistic curve- fit (4-PL) analysis to do this. If the samples have been diluted, the OD readout from the standard curve must be multiplied by the dilution factor used.

Step	Reagent	Volume	Incubation	Wash	Notes	
1	Standard and Samples	100 µL	120 min	4 times	Cover Wells incubate at 37°C	
2	Diluent Detection antibody, HRP-conjugated Solution	100 µL	40 min	4 times	Cover Wells incubate at 37°C	
3	TMB Substrate	100 µL	15-20 min	Do not wash	Incubate in the dark at 37°C	
4	Stop Solution	100 µL	0 min	Do not wash	-	
5	Read plate at 450 nm and 630 nm immediately after adding Stop solution. DO NOT exceed 5 minutes.					

9. Validation Data

9.1 Standard curve

These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.



(pg/mL)	0.D	Average	Corrected
0	0.0066 0.0094	0.008	-
39	0.173 0.1578	0.1654	0.1574
78	0.3314 0.3123	0.3219	0.3139
156	0.6094 0.5591	0.5843	0.5763
312	1.0372 0.9756	1.0064	0.9984
625	1.7072 1.6118	1.6595	1.6515
1250	2.4051 2.2961	2.3506	2.3426
2500	2.8291 2.7804	2.8048	2.7968

9.2 Precision

Intra-assay Precision (Precision within an assay) Three samples of known concentration were tested 20 times on one plate to assess intra-assay precision.

Inter-assay Precision (Precision between assays) Three samples of known concentration were tested in 24 separate assays to assess inter-assay precision.

Intra-assay Precision					
Sample	SD	CV%			
1	20	1,291.8	69.7	5.4	
2	20	281.7	13.7	4.9	
3	20	69.4	3.3	4.7	

Inter-assay Precision					
Sample	n	Mean (pg/mL)	SD	CV%	
1	24	1,232.9	45.8	3.7	
2	24	275.7	9.4	3.4	
3	24	72.1	2.6	3.6	

9.3 Recovery

The recovery of human MSLN spiked to three different levels throughout the range of the assay in various matrices was evaluated.

Sample Type		Average% of Expected	Range (%)
Human serum	1:320	98	92-107
Cell culture supernatant	1:8	90	89-91
Urine	1:16	92	89-95
Offile	1:32	91	88-94
Saliva	1:8	93	91-95

9.4 Sample values

Human serum/Urine/Saliva - human serum, urine and saliva samples were evaluated for the presence of human MSLN in this assay.

Sample Type	Mean (ng/mL)	Range (ng/mL)
Human serum (n=16)	30.0	12.9-137.0
Urine (n=8)	2.2	ND-6.5
Saliva (n=8)	1.0	0.2-2.4

ND*=Non-detectable

Cell culture supernatant - HepG2 (human hepatocellularcarcinoma cells) were cultured in DMEM supplemented with 10% fetal bovine serum, 2.5 mM L- glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin sulfate. An aliquot of the cell culture supernatantswasremoved, assayed for human MSLN, and measured 422.5 pg/mL.

9.5 Sensitivity

The minimum detectable dose of human MSLN is 3.7 pg/mL. This was determined by adding two standard deviations to the concentration corresponding to the mean O.D. of 20 zero standard replicates.

9.6 Linearity

To assess the linearity of the assay, samples were diluted with the appropriate **Sample Diluent** to produce samples with values within the dynamic range of the assay.

(The human serum was initially diluted 1:20. The urine was initially diluted 1:2.)

		Human serum	Cell culture supernatant	Urine	Saliva
1.2	Average% of Expected	100	100	100	100
1:2	Range (%)	-	-	-	-
1:4	Average% of Expected	95	106	102	108
	Range (%)	94-96	103-109	100-105	107-108
1:8	Average% of Expected	90	103	104	113
	Range (%)	89-91	102-103	100-109	112-114
1:16	Average% of Expected	94	94	107	120
	Range (%)	93-96	87-101	103-111	118-123

9.7 Specificity

This kit specifically recognizes native and recombinant human MSLN.

10. References

- 1. Zeng W, Pan J, Fang Z, Jia J, Zhang R, He M, Zhong H, He J, Yang X, Shi Y, Zhong B, Zeng J, Fu B, Huang M, Liu H. A Novel PD-L1-Containing MSLN Targeting Vaccine for Lung Cancer Immunotherapy. Front Immunol. 2022 Jun 20;13:925217.
- 2. Schoutrop E, El-Serafi I, Poiret T, Zhao Y, Gultekin O, He R, et al.. Mesothelin-Specific CAR T Cells Target Ovarian Cancer. Cancer Res (2021) 81:3022–35.
- 3. Weidemann S, Gagelmann P, Gorbokon N, Lennartz M, Menz A, Luebke AM, et al.. Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors. Biomedicines (2021) 9:397.
- 4. Le K, Wang J, Zhang T, Guo Y, Chang H, Wang S, et al.. Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC). Int J Med Sci (2020) 17:422–7.
- 5. Del Bano J, Florès-Florès R, Josselin E, Goubard A, Ganier L, Castellano R, et al.. A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer. Front Immunol (2019) 10:1593.